escherichia coli nissle 1917
Recently Published Documents


TOTAL DOCUMENTS

131
(FIVE YEARS 36)

H-INDEX

26
(FIVE YEARS 4)

2022 ◽  
Vol 23 (2) ◽  
pp. 594
Author(s):  
Haokun Shen ◽  
Zitong Zhao ◽  
Zengjue Zhao ◽  
Yuyi Chen ◽  
Linghua Zhang

Intestinal homeostasis is a dynamic balance involving the interaction between the host intestinal mucosa, immune barrier, intestinal microecology, nutrients, and metabolites. Once homeostasis is out of balance, it will increase the risk of intestinal diseases and is also closely associated with some systemic diseases. Probiotics (Escherichia coli Nissle 1917, Akkermansia muciniphila, Clostridium butyricum, lactic acid bacteria and Bifidobacterium spp.), maintaining the gut homeostasis through direct interaction with the intestine, can also exist as a specific agent to prevent, alleviate, or cure intestinal-related diseases. With genetic engineering technology advancing, probiotics can also show targeted therapeutic properties. The aims of this review are to summarize the roles of potential native and engineered probiotics in oncology, inflammatory bowel disease, and obesity, discussing the therapeutic applications of these probiotics.


2021 ◽  
Vol 19 (4) ◽  
pp. 478-481
Author(s):  
Jihye Park ◽  
Da Hye Kim ◽  
Soochan Kim ◽  
Hyun Woo Ma ◽  
I Seul Park ◽  
...  

mSphere ◽  
2021 ◽  
Author(s):  
Jean-Philippe Nougayrède ◽  
Camille V. Chagneau ◽  
Jean-Paul Motta ◽  
Nadège Bossuet-Greif ◽  
Marcy Belloy ◽  
...  

Nissle 1917 is sold as a probiotic and considered safe even though it has been known since 2006 that it harbors the genes for colibactin synthesis. Colibactin is a potent genotoxin that is now linked to causative mutations found in human colorectal cancer.


Gene ◽  
2021 ◽  
pp. 145890
Author(s):  
Sathyanarayanan Jayashree ◽  
Ramamoorthy Sivakumar ◽  
Raman Karthikeyan ◽  
Paramasamy Gunasekaran ◽  
Jeyaprakash Rajendhran

2021 ◽  
Author(s):  
Roger Geiger ◽  
Fernando Canale ◽  
Camilla Basso ◽  
Gaia Antonini ◽  
Michela Perotti ◽  
...  

Abstract The availability of L-arginine in tumors is a key determinant of an efficient anti-tumor T cell response. Consequently, elevation of typically low L-arginine levels within the tumor may greatly potentiate the anti-tumor responses of immune checkpoint inhibitors, such as PD-L1 blocking antibodies. However, currently no means are available to locally increase intra-tumoral L-arginine levels. Here, we used a synthetic biology approach to develop an engineered probiotic Escherichia coli Nissle 1917 strain that colonizes tumors and continuously converts ammonia, a metabolic waste product that accumulates in tumors4, into L-arginine. Colonization of tumors with these bacteria elevated intra-tumoral L-arginine concentrations, increased the amount of tumor-infiltrating T cells, and had striking synergistic effects with PD-L1 blocking antibodies in the clearance of tumors. The anti-tumor effect of the living therapeutic was mediated by L-arginine and was dependent on T cells. These results show that engineered microbial therapies enable metabolic modulation of the tumor microenvironment leading to enhanced efficacy of immunotherapies.


Biomolecules ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. 738
Author(s):  
Jiayu Ye ◽  
Lauren A. E. Erland ◽  
Sandeep K. Gill ◽  
Stephanie L. Bishop ◽  
Andrea Verdugo-Meza ◽  
...  

The use of live biotherapeutic products (LBPs), including single strains of beneficial probiotic bacteria or consortiums, is gaining traction as a viable option to treat inflammatory-mediated diseases like inflammatory bowel disease (IBD). However, LBPs’ persistence in the intestine is heterogeneous since many beneficial bacteria lack mechanisms to tolerate the inflammation and the oxidative stress associated with IBD. We rationalized that optimizing LBPs with enhanced colonization and persistence in the inflamed intestine would help beneficial bacteria increase their bioavailability and sustain their beneficial responses. Our lab developed two bioengineered LBPs (SBT001/BioPersist and SBT002/BioColoniz) modified to enhance colonization or persistence in the inflamed intestine. In this study, we examined colon-derived metabolites via ultra-high performance liquid chromatography-mass spectrometry in colitic mice treated with either BioPersist or BioColoniz as compared to their unmodified parent strains (Escherichia coli Nissle 1917 [EcN] and Lactobacillus reuteri, respectively) or to each other. BioPersist administration resulted in lowered concentrations of inflammatory prostaglandins, decreased stress hormones such as adrenaline and corticosterone, increased serotonin, and decreased bile acid in comparison to EcN. In comparison to BioColoniz, BioPersist increased serotonin and antioxidant production, limited bile acid accumulation, and enhanced tissue restoration via activated purine and pyrimidine metabolism. These data generated several novel hypotheses for the beneficial roles that LBPs may play during colitis.


Sign in / Sign up

Export Citation Format

Share Document